Q3 2019 EPS Estimates for Neuronetics Inc (NASDAQ:STIM) Cut by William Blair

Neuronetics Inc (NASDAQ:STIM) – William Blair cut their Q3 2019 earnings per share estimates for Neuronetics in a report issued on Tuesday, August 6th, according to Zacks Investment Research. William Blair analyst M. Kaczor now expects that the company will post earnings of ($0.41) per share for the quarter, down from their prior forecast of ($0.40). William Blair also issued estimates for Neuronetics’ Q4 2019 earnings at ($0.41) EPS, FY2019 earnings at ($1.62) EPS, Q1 2020 earnings at ($0.42) EPS, Q2 2020 earnings at ($0.41) EPS, Q3 2020 earnings at ($0.45) EPS, Q4 2020 earnings at ($0.44) EPS and FY2020 earnings at ($1.73) EPS.

Other analysts also recently issued reports about the company. Zacks Investment Research raised Neuronetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. ValuEngine downgraded Neuronetics from a “buy” rating to a “hold” rating in a research report on Thursday, June 27th.

Shares of NASDAQ:STIM opened at $9.65 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.95 and a current ratio of 6.10. The firm has a market cap of $184.85 million, a P/E ratio of -3.59 and a beta of 0.97. The business’s 50 day simple moving average is $11.71 and its two-hundred day simple moving average is $14.31. Neuronetics has a 52-week low of $8.90 and a 52-week high of $39.39.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.04. The business had revenue of $16.57 million for the quarter, compared to analyst estimates of $15.80 million. Neuronetics had a negative return on equity of 37.75% and a negative net margin of 43.85%.

A number of large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its position in Neuronetics by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 31,506 shares of the company’s stock worth $394,000 after buying an additional 1,270 shares during the last quarter. Advisor Group Inc. purchased a new stake in Neuronetics in the fourth quarter worth $27,000. BNP Paribas Arbitrage SA purchased a new stake in Neuronetics in the first quarter worth $41,000. Bank of America Corp DE increased its position in Neuronetics by 967.7% in the fourth quarter. Bank of America Corp DE now owns 5,787 shares of the company’s stock worth $111,000 after buying an additional 5,245 shares during the last quarter. Finally, Northern Trust Corp increased its position in Neuronetics by 4.6% in the second quarter. Northern Trust Corp now owns 133,618 shares of the company’s stock worth $1,671,000 after buying an additional 5,877 shares during the last quarter. 81.15% of the stock is owned by institutional investors and hedge funds.

In other Neuronetics news, insider Daniel Guthrie sold 3,685 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $14.53, for a total value of $53,543.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 12.00% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Featured Story: Rule of 72

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.